Diagnosis and Management of Acromegaly in 2012
treatment outcomes in 166 patients with acromegaly, J Clin Endocrinol Metab, 2009;94:523–7.
28. Melmed S, Colao A, Barkan A, et al., Guidelines for acromegaly management: an update, J Clin Endocrinol Metab 2009;94:1509-1517.
29. Giustina A, Chanson P, Bronstein MD, et al., A consensus on criteria for cure of acromegaly, J Clin Endocrinol Metab, 2010;95:3141–8.
30. Dina TS, Feaster SH, Laws ER, Jr, Davis DO, MR of the pituitary gland postsurgery: serial MR studies following transsphenoidal resection, AJNR Am J Neuroradiol, 1993;14:763–9.
31. Carlsen SM, Lund-Johansen M, Schreiner T, et al., Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial, J Clin Endocrinol Metab, 2008;93:2984–90.
32. Mao ZG, Zhu YH, Tang HL, et al., Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial, Eur J Endocrinol, 2010;162:661–6.
33. Khan ZH, Rasouli MR, Intubation in patients with acromegaly: experience in more than 800 patients, Eur J Anaesthesiol, 2009;26:354–5.
34. Damjanovic SS, Neskovic AN, Petakov MS, et al., High output heart failure in patients with newly diagnosed acromegaly, Am J Med, 2002;112:610–6.
35. Hradec J, Kral J, Janota T, et al., Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog), Am J Cardiol 1999;83:1506–9, A1508.
36. Lombardi G, Colao A, Marzullo P, et al., Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study, J Endocrinol Invest, 2002;25:971–6.
37. Katznelson L, Drug insight: Primary medical therapy of acromegaly, Nat Clin Pract Endocrinol Metab, 2006;2:109–17; quiz following 117.
38. Colao A, Pivonello R, Auriemma RS, et al., Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients, J Clin Endocrinol Metab, 2006;91:2112–8.
39. Machado EO, Taboada GF, Neto LV, et al., Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR, Growth Horm IGF Res, 2008;18:389–93.
40. Salvatori R, Nachtigall LB, Cook DM, et al., Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly, Pituitary, 2010;13:115–22.
41. Yetkin DO, Boysan SN, Tiryakioglu O, et al., Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide, Endocr J, 2007;54:459–64.
42. Trainer PJ, Drake WM, Katznelson L, et al., Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N Engl J Med, 2000;342:1171–7.
43. Van der Lely AJ, Hutson RK, Trainer PJ, et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, Lancet, 2001;358:1754–9.
44. Melmed S, Medical management of acromegaly – what and when?, Acta Endocrinol (Copenh), 1993;129(Suppl. 1):13–7.
45. Abs R, Verhelst J, Maiter D, et al., Cabergoline in the treatment of acromegaly: a study in 64 patients, J Clin Endocrinol Metab, 1998;83:374–8.
46. Sandret L, Maison P, Chanson P, Place of cabergoline in acromegaly: a meta-analysis, J Clin Endocrinol Metab, 2011;96:1327–35.
47. Cozzi R, Attanasio R, Lodrini S, Lasio G, Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients:
efficacy and lack of predictive value of prolactin status, Clin Endocrinol (Oxf), 2004;61:209–15.
48. Moyes VJ, Metcalfe KA, Drake WM, Clinical use of cabergoline as primary and adjunctive treatment for acromegaly, Eur J Endocrinol, 2008;159:541–5.
49. Schade R, Andersohn F, Suissa S, et al., Dopamine agonists and the risk of cardiac-valve regurgitation, N Engl J Med, 2007;356:29–38.
50. Colao A, Pivonello R, Rosato F, et al., First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial, Clin Endocrinol (Oxf), 2006;64:342–51.
51. Freda PU, Katznelson L, van der Lely AJ, et al., Long-acting somatostatin analog therapy of acromegaly: a meta-analysis, J Clin Endocrinol Metab, 2005;90:4465–73.
52. Murray RD, Melmed S, A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly, J Clin Endocrinol Metab, 2008;93:2957–68.
53. Melmed S, Sternberg R, Cook D, et al., A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly, J Clin Endocrinol Metab, 2005;90:4405–10.
54. Ezzat S, Kontogeorgos G, Redelmeier DA, et al., In vivo responsiveness of morphological variants of growth hormone- producing pituitary adenomas to octreotide, Eur J Endocrinol, 1995;133:686–90.
55. Colao A, Ferone D, Lastoria S, et al., Prediction of efficacy of octreotide therapy in patients with acromegaly, J Clin Endocrinol Metab, 1996;81:2356–62.
56. Ghigo E, Biller BM, Colao A, et al., Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy, J Endocrinol Invest, 2009;32:924–33.
57. Neggers SJ, de Herder WW, Janssen JA, et al., Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients, Eur J Endocrinol, 2009;160:529–33.
58. Buhk JH, Jung S, Psychogios MN, et al., Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study, J Clin Endocrinol Metab, 2010;95:552–8.
59. Schreiber I, Buchfelder M, Droste M, et al., Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study, Eur J Endocrinol, 2007;156:75–82.
60. Bonert VS, Kennedy L, Petersenn S, et al., Lipodystrophy in patients with acromegaly receiving pegvisomant, J Clin Endocrinol Metab, 2008;93:3515–8.
61. Giustina A, Bonadonna S, Bugari G, et al., High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial, Eur J Endocrinol, 2009;161:331–8.
62. Van der Lely AJ, Bernabeu I, Cap J, et al., Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone, Eur J Endocrinol, 2011;164:325–33.
63. Jallad RS, Bronstein MD, Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide, Neuroendocrinology, 2009;90:82–92.
64. Trainer PJ, Ezzat S, D’Souza GA, et al., A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly, Clin Endocrinol (Oxf), 2009;71:549–57.
65. Katznelson L, Atkinson JL, Cook DM, et al., American Association of Clinical Endocrinologists Medical Guidelines for Clinical
Practice for the Diagnosis and Treatment of Acromegaly – 2011 update: executive summary, Endocr Pract, 2011;17:636–46.
66. Castinetti F, Morange I, Dufour H, et al., Radiotherapy and radiosurgery in acromegaly, Pituitary, 2009;12:3–10.
67. Barrande G, Pittino-Lungo M, Coste J, et al., Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center, J Clin Endocrinol Metab, 2000;85:3779–85.
68. Jenkins PJ, Bates P, Carson MN, et al., Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly, J Clin Endocrinol Metab, 2006;91:1239–45.
69. Minniti G, Jaffrain-Rea ML, Osti M, et al., The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas, Clin Endocrinol (Oxf), 2005;62:210–6.
70. Jallad RS, Musolino NR, Salgado LR, Bronstein MD, Treatment of acromegaly: is there still a place for radiotherapy?, Pituitary, 2007;10:53–9.
71. Terzolo M, Matrella C, Boccuzzi A, et al., Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features, J Endocrinol Invest, 1999;22:48–54.
72. Castinetti F, Taieb D, Kuhn JM, et al., Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion, J Clin Endocrinol Metab, 2005;90:4483–8.
73. Jezkova J, Marek J, Hana V, et al., Gamma knife radiosurgery for acromegaly – long-term experience, Clin Endocrinol (Oxf), 2006;64:588–95.
74. Pollock BE, Jacob JT, Brown PD, Nippoldt TB, Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission, J Neurosurg, 2007;106:833–8.
75. Attanasio R, Epaminonda P, Motti E, et al., Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study, J Clin Endocrinol Metab, 2003;88:3105–12.
76. Landolt AM, Haller D, Lomax N, et al., Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy, J Neurosurg, 1998;88:1002–8.
77. Minniti G, Gilbert DC, Brada M, Modern techniques for pituitary radiotherapy, Rev Endocr Metab Disord, 2009;10:135–44.
78. Landolt AM, Haller D, Lomax N, et al., Octreotide may act as a radioprotective agent in acromegaly, J Clin Endocrinol Metab, 2000;85:1287–9.
79. Littley MD, Shalet SM, Beardwell CG, et al., Radiation-induced hypopituitarism is dose-dependent, Clin Endocrinol (Oxf), 1989;31:363–73.
80. Minniti G, Traish D, Ashley S, et al., Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years, J Clin Endocrinol Metab, 2005;90:800–4.
81. Rowe J, Grainger A, Walton L, et al., Risk of malignancy after gamma knife stereotactic radiosurgery, Neurosurgery, 2007; 60:60–5; discussion 65–6.
82. Dworakowska D, Gueorguiev M, Kelly P, et al., Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines, Eur J Endocrinol, 2010;163:21–8.
83. Terzolo M, Reimondo G, Gasperi M, et al., Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy, J Clin Endocrinol Metab, 2005;90:84–90.
84. Pekkarinen T, Partinen M, Pelkonen R, Iivanainen M, Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors, Clin Endocrinol (Oxf), 1987;27:649–54.
85. Pelttari L, Polo O, Rauhala E, et al., Nocturnal breathing abnormalities in acromegaly after adenomectomy, Clin Endocrinol (Oxf), 1995;43:175–82.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84